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Abstract:  
In spite of the impressive progress in the investigation of hepatic encephalopathy (HE), the 
complex mechanisms underlying the onset and deterioration of HE are still not fully understood. 
Currently, none of the existing theories provide conclusive explanations on the symptoms that 
link liver dysfunction to nervous system disorders and clinical manifestations. This paper 
summarized the diagnostic and therapeutic approaches used for HE in modern medicine and 
traditional Chinese medicine and provided future perspective in HE therapies from the viewpoint 
of holistic and personalized Chinese medicine. 
 
Article: 
INTRODUCTION 
Hepatic encephalopathy (HE), also known as portosystemic encephalopathy, is defined as a 
spectrum of neuropsychiatric abnormalities in patients with liver dysfunction, after exclusion of 
other known brain diseases [1–3]. The aggravation of HE will result in hepatic coma or coma 
hepaticum, which may ultimately lead to death [4]. It is believed that the increase of harmful 
substances entering brain from blood is the main cause of HE, and currently the identified causal 
factors for HE are ammonia [5, 6], γ-aminobutyric acid (GABA) [7, 8], false neurotransmitters 
[9, 10], and the imbalance of certain amino acids in plasma [11, 12]. In spite of the impressive 
progress in research aiming to uncover the etiology of HE, the complex mechanisms underlying 
the onset and deterioration of HE and related conditions are still not fully understood. Currently, 
none of the existing theories provide conclusive explanations on the symptoms that link liver 
dysfunction to nervous system disorders and clinical manifestations. Generally, it has been 
accepted that high blood ammonia, which is not properly metabolized in and removed from liver 
because of the hepatic dysfunction, is closely associated with dysregulation of central nervous 
system (CNS). The elevation of neurotoxins such as ammonia in blood and CNS impairs the 
related neurotransmitter system and leads to the functional disorder of CNS. Such a complicated 
pathology of HE implies the possibility of systematic involvement of multiple organs in 
orchestrating the development of HE. Therefore, it is necessary to adopt a systems strategy with 
interdisciplinary studies to understand how dysregulated metabolites disturb the organ-organ 
(liver-brain) interactions and eventually to uncover the mechanisms of HE at a systems level. 
 
Traditional Chinese medicine (TCM) typically involves a personalized diagnosis and the use of 
herbal formulae of between 10–20 separate herbal ingredients selected from material medica of 
several thousand herbs that are prepared either as a boiled decoction, as dried herbal extracts, or 
taken as pills [13]. Diagnostic and therapeutic treatment principles are framed according to the 
TCM understanding of pathological processes. A good practice of TCM is usually considered to 
require a TCM pattern identification based on clinical manifestation followed by the use of 
individualized herbal decoctions that are adapted to address the particular TCM pattern of each 
patient [14]. Since the treatment will change following the changing TCM patterns and clinical 
manifestations. TCM is a dynamic and highly responsive system of medicine that resonates 
strongly with the increasing emphasis within systems biology strategy for the use of both 
multiple approaches to achieve optimum diagnosis and individualized treatments to take into 
account variable responses to modern drugs. 
 
In the theory of TCM, the onset of HE is due to the invasion of damp and heat in triple burners 
which leads to phlegm and stagnation of Qi, which eventually causes the disability of thinking in 
HE patients. Such a traditional theory appears to be consistent with the modern theories of HE 
etiology. Given the holistic and personalized nature of TCM, HE and its clinical manifestations 
are divided into various TCM patterns (phenotypes) with different characteristics, which 
necessitate different therapeutic methods in TCM. In this paper, we summarized the theories and 
therapeutic methods of HE both in modern medicine and TCM and provided future perspective 
in HE therapies from the viewpoint of systems biology. 
 
THE DIAGNOSIS OF HE IN MODERN MEDICINE 
To date, there are no gold-standard diagnostic procedures for HE with high sensitivity and 
specificity in modern medicine. HE patients usually have advanced chronic liver disease and thus 
have many of the physical and laboratory stigmata associated with severe hepatic dysfunction. 
Physical features may include muscle wasting, jaundice, ascites, palmar erythema, edema, spider 
telangiectasias, and fetor hepaticus [15, 16]. However, some of these features (such as muscle 
wasting, spider telangiectasias, and palmar erythema) are usually absent in HE patients with 
fulminant hepatic failure who are previously healthy, because the development of these features 
requires a relatively longer period of hepatic dysfunction. As a result, substantial technical and 
laboratory examinations are needed for diagnosis of HE patients, which include psychological 
test, electrophysiological test, and imaging. 
 
Psychological Test 
The most common tests used in clinics are number connection test (NCT), line tracking test 
(LTT), serial dotting test (SDT), continuous reaction time (CRT), critical frequency 
scintillometer (CFS), and wisconsin Ccard sorting test (WCST). The combination of these tests 
will increase the accuracy of HE determination, avoiding false diagnosis based on a single test. 
For example, HE psychological testing, a combined test group including NCT, DST, LTT and 
SDT, has become a rapid and practical procedure that takes less than 20 minutes and achieves 
96% sensitivity and 100% specificity. 
 
Electrophysiological Test 
Electrophysiological and electropsychological changes can be tested by electroencephalogram 
(EEG) and brain electrical activity mapping (BEAM). EEG can be used not only as an evaluation 
tool but for early diagnosis as well. However, it may be difficult to evaluate the disease 
objectively as it lacks specificity [17]. Recently, based on the EEG assessment, a test called 
artificial neural network-expert system (ANNES) with the computer analysis technology is 
proposed as an expert system to overcome this problem [18]. Additionally, analysis of the EEG 
utilizing a spatiotemporal decomposition technique (SEDACA) provides significantly more 
diagnostic information on the neuropsychiatric status of HE patients than obtained 
conventionally [19]. 
 
Imaging 
The imaging methods for HE include computerized tomography (CT) and magnetic resonance 
imaging (MRI), magnetic resonance spectroscopy (MRS), single photon emission computed 
tomography (SPECT), and positron emission tomography (PET) [20]. CT and MRI are mainly 
used to detect brain morphology, such as hydrocephalus in the acute HE patients and 
encephalatrophy, especially in lobus frontalis in the chronic HE patients [21]. MRS is mainly 
used to detect the changes of compounds in cells, analyzing the concentrations of such 
metabolites as glycoconjugates, amino acids, cholines, phospholipids, and creatine to help early 
diagnosis. Both SPECT and PET are used extensively to assess brain perfusion, which is 
typically less “active” in HE patients than in healthy people. 
 
THERAPIES OF HE IN MODERN MEDICINE 
The treatments for HE typically include (1) elimination or correction of the underlying factors 
participating in HE, (2) restoring metabolic homeostasis, (3) promoting regeneration of liver 
cells, (4) antibiotic agents that inhibit mucosal glutaminase in the intestine to reduce ammonia 
production in the gut, and (5) artificial liver support or liver transplantation [22–26]. Most 
patients show clinical signs of improvement in the symptoms of HE within 24–48 hours of 
initiation of treatment. Serum levels of ammonia might lag behind the clinical response. 
 
Dietary Regulation of Homeostasis 
Restriction of protein intake in diet is preferred for HE therapy. It is advised to consume more 
calories from vegetable and dairy protein, because vegetable protein is rich in branched-chain 
amino acids and nonabsorbent fiber, which are beneficial for the balance of normal gut 
microbiota and acidifying the intestinal tract. It is also necessary to uptake sufficient 
carbohydrate and vitamins, that is, vitamin C can reduce the level of pH in blood and divert 
ammonia from brain to blood [27–29]. On the other hand, drinking sufficient water is helpful for 
maintaining homeostasis of the body, which protects body from hypokalemia, hyperkalemia, 
hyponatremia, hypocalcemia, hypomagnesemia, and metabolic alkalosis. Additionally, some 
other ways are available for keeping the homeostasis such as plasma or albumin transfusion, to 
increase plasma colloid osmotic pressure, improve hypoxemia and hydrocephalus, and prevent 
hemorrhage and bacterial infection. 
 
Elimination of Blood Ammonia 
Elimination of blood ammonia is critical for HE treatment. Lactulose is widely used as a 
standard medicine to evaluate the effect of new drug for HE [30]. Besides, Lactitol is also well 
practiced for HE therapy with comparable effect to lactulose, but with better tolerance [31, 32]. 
Although Neomycin is effective for HE patients, long-term usage is prohibited for its toxicity 
[33, 34]. Oral administration of L-7-ornithine-aspartate (OA) can effectively eliminate the level 
of blood ammonia [35]. Recent studies show that the concentration of blood ammonia in HE 
patients was significantly decreased by Rifaximin, as well as amelioration of the patients’ 
condition [36–38]. 
 
Supplementation of Branched-Chain Amino Acids 
The administration of branched-chain amino acids (BCAAs) may help adjust the abnormal ratio 
of BCAAs to aromatic amino acids (AAAs) crossing the blood-brain barrier (BBB), so that the 
symptom of HE can be improved. A recent meta-analysis has shown that patients with cirrhosis 
who receive BCAAs are more likely to recover from HE than those who do not receive this 
supplement [39]. BCAAs improve levels of serum albumin, increase progression-free survival, 
and reduce both the number of hospitalizations and the length of hospital stays in patients with 
cirrhosis [40]. These amino acids can be administered orally as well as intravenously. 
 
Use of False Neurotransmitter Antagonist 
According to the theory of false neurotransmitter for HE development [2, 10], antagonists of 
false neurotransmitter could be used for HE therapy, including bendopa, dopamine agonist 
Bromocriptine, and opium receptor Narcon. Bendopa could pass the BBB and flow into brain 
tissue and produce dopamine and norepinephrine by enzymatic catalysis, which are substitutes 
for the false neurotransmitter and help to recover nerve function. Bromocriptine could agitate 
postsynaptic dopamine receptor to upregulate prolactin with nerve transmitting function 
strengthened. Using Bromocriptine alone or with Lactulose together is especially effective to 
those chronic HE patients who are insensitive to Neomycin or Lactulose. Narcon can cross BBB 
easily and attenuate the inhibited effect on CNS caused by redundant opioid peptides. Clinical 
data showed that Narcon is helpful to improve the consciousness of HE patients. However, 
evidence has indicated that obvious variations exist in therapeutic effectiveness of these 
medicines on HE patients [41, 42]. 
 
TREATMENT OF HE IN TCM 
In TCM, the phenotype of HE is the result of impaired resistance to damp and heat environment 
(two of the six exogenous pathogens in TCM including wind, cold, heat, damp, dryness, and 
fire), along with the reduced function of middle burner (the middle part of triple burners in TCM, 
referring mainly to the organs located between diaphragm and navel, including stomach and 
spleen) to excrete toxic substances. The accumulated toxic substances in the middle burner 
spread to the triple burners (including upper, middle, and lower burner, covering all of the 
organs) and affect the upper orifices (upper orifices are the openings on the face, such as the 
eyes, ears, nose, and mouth). The essential substances of the organs are distributed through these 
orifices, so any pathologic change of these orifices contributes to a diagnosis of the disorders of 
these organs. The pathogenesis in TCM view is consistent with the modern medicine in that 
abnormal accumulation of metabolites, especially the production, absorption, and distribution of 
endotoxin in the patients with liver failure will cause the metabolic imbalance in blood. As a 
result, the therapeutic strategy for HE under TCM includes purgation and eliminating stasis in 
organs and inducing resuscitation, which is holistic and dynamic in nature. 
 
Table 1: The typing, prescription, and treatments for different syndromes of HE. 
Prescription Medicinal herb ingredients 
Invasion of pericardiuma by excessive heat and toxin 
Zi Xue Pill 
Gypsum Fibrosum, Gypsum Rubrum, Magnetitum, Talcum, Bubali Cornu, Saigae Tataricae Cornu, 
Aucklandiae Radix, Aquilariae Lignum Resinatum, Cimicifugae Rhizoma, Glycyrrhizae Radix et 
Rhizoma, Caryophylli Flos, Natrii Sulfas, Moschus, Cinnabaris 
Qing Ying Liang Xue Decoction Bubali Cornu, Salviae Miltiorrhizae Radix et Rhizoma, Artemisiae Scopariae Herba, 
An Gong Niu Huang Pill Imperatae Rhizoma, Bergenia Herba, Paeoniae Radix Rubra, Rehmanniae Radix, Moutan Cortex, Gardeniae Fructus Praeparatus, Rhei Radix et Rhizoma 
Qing Wen Bai Du Oral Solution 
Bubali Cornu, Coptidis Rhizoma, Scutellariae Radix, Artemisiae Scopariae Herba, Lysimachiae 
Herba, Gypsum Fibrosum, Anemarrhenae Rhizoma, Platycodonis Radix, Rhei Radix et Rhizoma, 
Gardeniae Fructus, Smilacis Glabrae Rhizoma, Alismatis Rhizoma, Plantaginis Semen, Aurantii 
Fructus Immaturus, Forsythiae Fructus, Rehmanniae Radix, Lophatheri Herba, Scrophulariae Radix 
Huang Lian Decoction for Detoxification Plus Zhi Bao Pill 
Coptidis Rhizoma, Phellodendri Chinensis Cortex, Scutellariae Radix, Gardeniae Fructus, Rhei Radix 
et Rhizoma Bubali Cornu, Bovis Calculus, Eretmochelys imbricata, Ambrum, Cinnabaris, Realgar, 
Moschus, Benzoinum 
Yin Chen Hao Decoction Artemisiae Scopariae Herba, Gardeniae Fructus, Rhei Radix et Rhizoma 
Wu Wei Detoxification Oral Liquid Lonicerae Japonicae Flos, Taraxaci Herba, Violae Herba, Begonia Fimbristipula Herba, Eupolyphaga or Steleophaga 
Xi Jiao Di Huang Decoction Bubali Cornu, Rehmanniae Radix, Paeoniae Radix Rubra, Moutan Cortex, Arnebiae Radix 
Pattern of mental confusion by dampness and phlegmb accumulation 
Yin Chen Wu Ling Dispersing agent Artemisiae Scopariae Herba, Polyporus, Alismatis Rhizoma, Atractylodis Macrocephalae Rhizoma, Poria, Cinnamomi Ramulus 
Phlegm-removing Decoction with Da Huang 
Arisaematis Rhizoma, Pinelliae Rhizoma, Aurantii Fructus Immaturus Poria, Citri Exocarpium 
Rubrum, Cinnabaris, Acori Tatarinowii Rhizoma, Atractylodis Macrocephalae Rhizoma, Caryophylli 
Flos, Aquilariae Lignum Resinatum, Santalum album, 
Su He Xiang Pill 
Olibanum, Piperis Longi Fructus, Bubali Cornu, Benzoinum, Aucklandiae Radix, Cyperi Rhizoma, 
GinsengRadix et Rhizoma, Bambusae Caulis In Taenias, Glycyrrhizae Radix et Rhizoma, Rhei Radix et 
Rhizoma, Styrax, Moschus, Borneolum Syntheticum 
Ju Fang Zhi Bao Pill Bubali Cornu, Bovis Calculus, Eretmochelys imbricata, Ambrum, Cinnabaris, Realgar, Moschus, Benzoinum 
Yin Chen Si Ling Decoction Artemisiae Scopariae Herba, Poria, Alismatis Rhizoma, Polyporus, Gardeniae Fructus 
Chang Pu Yu Jin Decoction Acori Tatarinowii Rhizoma, Curcumae Radix, Arisaema Cum Bile, Pinelliae Rhizoma, Magnoliae Officinalis Cortex, Myristicae Semen, Polygalae Radix, Forsythiae Fructus, Pogostemonis Herba 
Pattern of Yinc deficiency of liver and kidney and Yangc excess of Liver 
Yi Guan Decoction Rehmanniae Radix, Angelicae Sinensis Radix, Lycii Fructus, Glehniae Radix, Ophiopogonis Radix, Toosendan Fructus 
Ling Yang Jiao Decoction 
Saigae Tataricae Cornu, Testudinis Carapax Et Plastrum, Rehmanniae Radix, Ligustri Lucidi Fructus, 
Eclipse Prostrala Herba, Dendrobii Caulis, Margaritifera Concha, Moutan Cortex, Paeoniae Radix 
Rubra, Bupleuri Radix, Prunellae Spica, Chrysanthemi Flos, Haliotidis Concha, Carthami Flos, 
Persicae Semen, Angelicae Sinensis Radix, Chuanxiong Rhizoma, Trogopteri xanthipes stool, Cyperi 
Rhizoma, Corydalis Rhizoma, Artemisiae Scopariae Herba 
Pattern of exhaustion of Yin and Yang, and disturbance in spirit 
Pulse-Activating Powder Ginseng Radix Et Rhizoma, Ophiopogonis Radix, Schisandrae Chinensis Fructus 
Xi Jiao Di Huang Decoction Bubali Cornu, Rehmanniae Radix, Paeoniae Radix Alba or Paeoniae Radix Rubra, Moutan Cortex 
Shen Fu Long Mu Decoction 
Ginseng Radix Et RhizomaRubra, Aconiti Lateralis Radix Praeparata, Astragali Radix, Ostreae 
Concha, Corni Fructus, Polygonati Rhizoma, Rehmanniae Radix, Rehmanniae Radix Praeparata, 
Schisandrae Chinensis Fructus, Scrophulariae Radix, Ophiopogonis Radix, Adenophorae Radix 
aPericardium refers to an anatomical membrane surrounding heart, and physiologically it protects the heart. When exogenous pathogens invade the heart, the pericardium is always 
the first to be attacked. Invasion of the pericardium by pathogenic heat gives rise to symptoms of mental disturbances such as coma and delirium in TCM. 
bPhlegm is usually secreted by dysfunction of lung and spleen, and occasionally by the consumption of body fluids by fire and heat evils. A disharmony of body fluids can produce 
either external, visible phlegm, such as sputum secreted by the respiratory tract, or internal, invisible phlegm. 
cThe Yin-Yang theory believes that the normal life activities of the human body result from the harmonious relation of the unity of opposites between Yin and Yang. The imbalance 
between Yin and Yang is one of the basic pathogenesis of a disease. All the pathological changes can be summarized as excess or deficiency of Yin or Yang. To be more concrete, 
“Yang excess leads to heat syndrome while Yin excess causes cold syndrome”; “Yang deficiency results in cold syndrome while Yin deficiency causes heat syndromes”; “Yang 
deficiency affects Yin while Yin deficiency affects Yang.” 
 
 
Treatment of HE according to TCM Patterns 
TCM pattern differentiation is a method to analyze and characterize the clinical manifestations of 
a disease, a process in which the geographical location, nature, occurrence, and development of 
the diseased and pathogenic factors are taken into account. Once a specific pattern of an HE 
patient is identified, a specific treatment strategy will be used to correct or mitigate the pattern of 
the patient. Table 1 provides a summary of typical TCM patterns of HE and their subsequent 
treatments. 
 
TCM Pattern of HE—Invasion of Pericardium by Excessive Heat Toxin. The main clinical 
manifestation of this pattern is characterized as follows. High fever appears at night, severe 
jaundice with clear yellowing of the body and deteriorating fast, either coma and 
unconsciousness or disturbed emotion even delirium, constipation inducing distension and 
ascites, hemorrhinia, hematemesis, hematochezia, bright red tongue substance with yellow and 
dry tongue coating, taut thready or taut rapid pulse. Treatment should be cleansing the heat toxin 
and inducing resuscitation. TCM prescriptions commonly used in clinic are Purple Snowy 
Powder [43], Qing Ying Liang Xue Tang and Cow-bezoar Bolus for Resurrection [44], 
Antipyretic and Antitoxic Decoction [45], Coptidis Decoction for Detoxification, combined with 
Rhubarb and Treasured Bolus [46], and a new prescription made with some of the herbs from the 
three prescriptions Herbae Artemisiae Capillariae Decoction, Antiphlogistic Decoction of Five 
Drugs, and Cornus Rhinoceri and Rehmannia Decoction [45]. 
 
TCM Pattern of HE—Dampness and Phlegm Accumulation Causing Mental Confusion. 
The main clinical manifestation of this syndrome is characterized as follows. Apparent symptom 
of jaundice, dark complexion, coma with nausea and vomiting, abdominal distension, high fever 
at the same time, urine with yellow color and small amount, exhaustion, chest distress, 
abdominal flatulence, bitterness in the mouth, dark red tongue substance with white greasy or 
yellow greasy tongue coating, soft and rolling pulse or soft and thready pulse. Treatment should 
be clearing away dampness, dispelling Phlegm and inducing resuscitation. TCM prescriptions 
commonly used in clinics are Herbae Artemisiae Capillariae Decoction [47], Artemisiae 
Scopariae and Poriae Powder [48], Phlegm-removing decoction, combined with Rhubarb and 
Storax Pill [46], Jufang Zhibao Dan [47], Yin Chen Si Ling Decoction, and Changpu Yujin 
Decoction [45]. 
 
TCM Pattern of HE—Yin Deficiency of Liver and Kidney Coupled with Yang Excess of 
Liver. The main clinical manifestation of this syndrome is characterized as follows. Swarthy 
complexion, thin shape, faintness, coma, distracted, jerking movements in the extremities, red 
and dry tongue substance with little tongue coating, taut thready or taut rapid pulse. Treatment 
should be nourishing liver and kidney, and expelling wind and heat. TCM prescriptions 
commonly used in clinic are Du Xiao Ke Li [49], Yiguan Decoction [50], Cornu Satgae 
Decoction, and Subphrenic Recesses [45]. 
 
TCM Pattern of HE—Exhaustion of Yin and Yang Coupled with Disturbance in Spirit. 
The main clinical manifestation of this syndrome is characterized as follows. Dottiness, coma, 
pale complexion, cold extremities, carphology, syncope with convulsion, slow reaction, weak 
breath, diaphoresis, incontinence of urine and feces, pale tongue substance without tongue 
coating, feeble and impalpable pulse. Treatment should be supplementing Qi and nourishing Yin, 
reduce resuscitation, and recuperate depleted Yang. TCM prescriptions commonly used in clinic 
are Pulse-Activating Powder or Cornus Rhinoceri and Rehmanniae Decoction [51], Shen Fu 
Long Mu Tang, or Ginseng Decoction [45]. 
 
TCM Treatmen—Purging Organs and Opening Orifices 
The pathogenesis of HE mostly includes the deficiency of liver and kidney, phlegm retention and 
blood stasis, failure of Yang and Yin to raise and fall, respectively, which could be regarded as 
the declining function in distributing nutrients to the organ and excretion out of the organ, 
leading to the symptoms like coma, convulsion, and mental confusion [52]. The TCM pattern of 
the excess phlegm and serum stasis with the deficiency in both Yin and Yang of Qi and blood 
affect the mental stability. A clinical TCM retrospective survey with a large number of HE 
patients (𝑛 = 1072) and a prospective survey with 133 HE subjects revealed that the main cause 
of liver failure is a combination of toxin, phlegm, and blood stasis entangled in the body along 
with dampness, heat, and pestilence invasion [53]. Therefore, the TCM treatment approaches 
involve removing toxin, expelling blood stasis, and eliminating phlegm have been applied in the 
clinical treatment of HE. Several representative clinical studies are described using this approach 
in the following. 
 
Rhubarb (Rhei Radix and Rhizoma) is a potent herb with purging activity, which can relieve 
internal heat and promote blood circulation by removing blood stasis and normalizing 
gallbladder to cure jaundice [54–56]. Li and Ma [57] applied a decoction of a single medicinal 
plant, Rhubarb, through colon infusion in 30 HE patients. About 30 g of Rhubarb was prepared 
to decoction in a 200 mL of water as an enema. This decoction was administered 1-2 times daily 
for 10 days as a course of treatment. Six patients experienced “complete remedy” (CR, defined 
as reaching and maintaining a conscious and lucid state of mind for 3 weeks after dose), 18 
patients experienced “partial remedy” (PR, significant improvement of the symptoms), while 6 
patients had no effect. The total efficacy (CR + PR) was 80%. 
 
Lv and Li [58] applied a TCM agent, Tongfu Xiere Decoction, containing Rhubarb, Dandelion, 
Magnolia Bark, Citri Immaturus, and Fructus Mume, to 64 HE patients, with an attempt to 
relieve internal heat, and cool, promote blood flow, and eliminate phlegm and freeing channels. 
The patients were divided into two groups, a control group in which all subjects received 
intravenous infusion of 40 mL of Qingkailing (a TCM drug) injection, 250 mL of BCAA or 10 g 
of Hepa Merz, once a day, and a TCM group in which Tongfu Xiere Decoction was applied in 
addition to the treatments in the control group. The decoction was prepared as an enema and 
administered through colon infusion at 250 mL a day. Therapeutic efficacy in TCM group 
reached 93.94% while the control group reached 80.65%. 
 
A combined Narcon and Rhubarb therapy for 62 HE patients was conducted by Huang [59] 
recently. The patients were randomly divided into two groups, conventional therapy group (𝑁 = 
24) with an integrated approach comprising antibiotics treatment, balancing electrolytes, amino 
acids, and pH in body fluid, and so forth, and the treatment group (𝑁 = 38), in which intravenous 
infusion of Narcon and colon infusion of Rhubarb decoction were applied in addition to the 
approach used in the conventional therapy group. Narcon was infused at a dose of 4 mg in 
500 mL of 5% Glucose, at 0.3 mg/h. The decoction of 30 g of Rhubarb in 500 mL water was 
applied once a day. The results showed a significant improvement in effectiveness in the 
treatment group with 94.7% efficacy (defined as showing a conscious state <48 h after dose) 
compared to an efficacy of 66.7% in the conventional therapy group. 
 
A similar clinical investigation was conducted using the decoction of Rhubarb as an enema to 
treat 60 HE patients at the First Hospital affiliated to Guangxi University of Traditional Chinese 
Medicine. The patients were randomly divided into two groups, conventional therapy group (𝑁 = 
30) with an integrated approach, and the treatment group (𝑁 = 30) with colon infusion of a 
decoction of Rhubarb and Mume Fructus were applied in addition to the approach used in the 
conventional therapy group. The decoction of Rhubarb and Fructus Mume (30 g : 30 g in 100 mL 
water) was applied once a day. After a 3-day course of treatment, the total effective rate (defined 
as HE symptoms improved by one stage (0–4 stages) within 48 h after dose) in the treatment 
group was 83.33%, higher than that (56.67%) in conventional therapy group [60]. 
 
SUMMARY AND PROSPECT 
Summary of Therapies for HE with Modern Medicine and TCM 
The current diagnoses of HE are still based on experimentalism lacking accurate and objective 
evaluation of the pathology in modern medicine due to the complexity of the HE pathogenesis. 
Current treatment of HE is focused on a comprehensive management of disease symptoms and 
improvement of patients’ quality of lives, with less satisfactory effectiveness in reversing the 
pathological course of HE. On the other hand, long-term exposure to therapeutic drugs also 
results in drug resistance and dependence. As a result, no universally effective treatment has 
been generated in modern medicine. However, the successful use of TCM therapeutic 
approaches over the past decades suggests that alternative approaches be taken into consideration 
for HE therapy with holistic and personalized views and a multi-level and multipathway 
adjustment strategy. For example, the treatment with the strategy of purging organs and 
removing blood stasis has been increasingly accepted for HE therapy in TCM. Nevertheless, 
more well-designed studies should be conducted to further evaluate the clinical efficacy of TCM 
approaches and elucidate the complicated mechanisms of TCM treatment for HE patients. 
 
Prospective 
The brain and liver are key targets for damage induced by dysregulated metabolites often 
associated with gut-generated signals. Thus the gut-liver-brain axis is crucial for coordinating 
homeostasis and health. Therefore, interdisciplinary studies of how dysregulated metabolites 
disturb the gut-liver-brain interactions will uncover novel mechanisms of HE, which are essential 
for understanding the pathogenesis at a systemic level. Such knowledge is the basis for 
development of effectively preventive and therapeutic strategies in most-at-risk populations. 
 
Recent studies suggest that HE seems to be the result of the energy metabolism defects in brain, 
neurotransmitter abnormity, and mutation of the receptors on the membrane of neuron. Thus, the 
pathogenesis of HE might be a result of systematic dysfunctions in multiple organs. 
Metabolomics, an important element for systems biology with genomics, transcriptomics, and 
proteomics, has been increasingly applied in identifying and quantifying significantly altered 
metabolites in cell, tissue, organ, or organism, as the end products of biological processes 
reflecting pathological change of diseases or the effects of medicine to the body. Serum 
metabolite profiling with 1H-NMR has been implemented in patients with normal, cirrhosis, or 
minimal HE, in which substantial differentiated metabolites have been identified among different 
groups [61]. The application of metabolomics to the study of HE will help understand the 
pathogenesis and provide a new method for early diagnosis of this disease. Metabolomics may 
be an effective technique linking quantitative changes of metabolites to syndromes of TCM 
because the various syndromes of TCM may result from global metabolic imbalances in the 
patients. As a result, metabolomics can be applied as a holistic profiling tool to unveil the veil of 
TCM diagnosis and therapies of HE. Such a novel clinical approach coupled with TCM 
strategies is expected to make breakthrough discoveries in the areas of characterizing metabolic 
phenotypes of HE, developing diagnostic and treatment biomarkers, and identifying herbal 
medicines suitable for HE treatment. 
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